Meat consumption must fall by at least 75 percent
If our planet is to continue feeding us in the future, rich countries must significantly reduce their meat consumption by at least 75% suggests a new study by German researchers.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1328 entries already.
Entries by Thomas Gabrielczyk
Vigeneron updates gene therapy collab with Daiichi Sankyo
/in News/by Thomas GabrielczykViGeneron and Daiichi Sankyo have agreed a follow-on collaboration to evaluate vgAAVs as vectors for Daiichi Sankyo novel treatment of prevalent eye diseases.
Single-use market to reach $20.8bn by 2026
/in News/by Thomas GabrielczykAnalysts from Markets & Markets today released the report "Single use Bioprocessing Market by Product.
Study shows advantages of cellular agriculture
/in News/by Thomas GabrielczykNovel foods derived from cell culture instead of animals reduce the environmental impact of diets, water and land use by 80%, report Finnish researchers.
EMA delays Valneva vaccine approval
/in News/by Thomas GabrielczykThe approval of Valneva’s Corona vaccine is delaying. The European Medicines Agencys CHMP requested additional data.
Mimetas BV participating in 325m cancer funding
/in News/by Thomas GabrielczykOrgan-on-chip disease model specialist Mimentas BV participates in a 325m funding to accelerate preclinical cancer R&D in the Netherlands.
Hansa Biopharmas imlifidase advances to Phase III testing
/in News/by Thomas GabrielczykThe US Food & Drug Administration has given the green light for Phase III testing of Hansa Biopharmas imlifidase in anti-GBM disease.
GSK acquires Sierra Oncology for 1.9bn
/in News/by Thomas GabrielczykGlaxoSmithKline acquires California-based Sierra Oncology and a ready-for-approval product candidate for myelofibrosis.
Scientists print 3D cancer model
/in News/by Thomas GabrielczykA 3D tumour model developed by scientists enables drug screening in metastases
Affimed prices public offering to finance NK cell trials
/in News/by Thomas GabrielczykFollowing phantastic AFM13 data at AACR, Affimed N.V. prices it public offering at $84.4m.